The results of a large multicenter observational study investigating if anti-COVID-19 vaccination may have functional implications for immune checkpoint inhibitor treatment, in particular anti-PD-1 therapy (camrelizumab), were published in the Journal for ImmunoTherapy of Cancer. The study, which was led by Dr Jian Li from our institute, showed that the COVID-19 vaccine BBIBP-CorV did not increase severe anti-PD-1-related adverse events nor did it reduce the clinical efficacy of camrelizumab in patients with cancer.
Publication:
Impact of COVID-19 vaccination on the use of PD-1 inhibitor in treating patients with cancer: a real-world study
Mei Q, Hu G, Yang Y, Liu B, Yin J, Li M, Huang Q, Tang X, Böhner A, Bryant A, Kurts C, Yuan X, Li, J. J Immunother Cancer 2022 Mar;10(3):e004157.
